查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018546

核子醫學市場：2026-2032年全球市場預測（依產品類型、給藥途徑、應用、應用領域及最終用戶分類）

Nuclear Medicine Market by Product Type, Mode Of Administration, Usage, Application, End Users - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，核醫市場價值將達到 160.5 億美元，到 2026 年將成長至 177.2 億美元，到 2032 年將達到 338.7 億美元，複合年成長率為 11.25%。

主要市場統計數據
基準年 2025 160.5億美元
預計年份：2026年 177.2億美元
預測年份 2032 338.7億美元
複合年成長率 (%) 11.25%

核子醫學發展趨勢：推動全球醫療保健進步的現代診斷和治療創新基礎性見解

核子醫學已成為現代醫學的基石，它利用放射性同位素的獨特特性，實現了精準診斷和標靶治療。從早期的伽馬攝影機成像到如今先進的治療診斷學一體化（診斷治療）方法，核醫學領域不斷發展，以滿足日益成長的個人化醫療需求，並受益於分子生物學的進步以及成像設備和放射性藥物化學的持續創新。整個價值鏈上的相關人員——放射性藥物研發人員、設備製造商、臨床醫生和監管機構——都在應對不斷變化的臨床指南、不斷擴大的適應症以及日益嚴格的安全性和供應保障審查所帶來的挑戰。

從傳統的同位素方案到跨多種模式的突破性放射性藥物開發，識別正在重塑核子醫學的變革性變化。

核子醫學領域正經歷一場變革，這主要得益於放射性藥物發現的突破性進展和技術創新的整合。近年來，針對特定生物標記的新型分子示蹤劑層出不窮，使臨床醫生能夠以前所未有的靈敏度檢測病理過程。同時，數位成像檢測器和先進的斷層重建演算法不斷提升影像解析度和定量分析能力。這兩大趨勢正朝著融合正子斷層掃描（PET）、單光子發射電腦斷層掃描（SPECT）和電腦斷層掃描（CT）的混合平台發展，從而提供更全面的疾病觀點。

評估 2025 年美國關稅對核醫供應鏈、研究合作趨勢及放射性藥物跨境貿易流量的累積影響。

美國在2025年實施的關稅政策為核醫供應鏈帶來了新的複雜性，影響了同位素材料和影像設備的進口。隨著關鍵原料和特殊零件關稅的生效，製造商面臨日益成長的生產成本壓力和物流限制。為了因應這些變化，一些生產商正在調整籌資策略，投資建造國內同位素生產設施，並尋求垂直整合以減輕進口關稅的影響。

透過對產品類型、給藥方法、應用類別、臨床應用和最終用戶概況等關鍵市場細分進行深入分析，以明確策略方向。

市場區隔洞察揭示了一個支持策略規劃和資源分配的多面向框架。按產品類型分類，該行業可分為診斷放射性藥物（包括正電子發射斷層掃描 (PET) 和單光子發射電腦斷層掃描 (SPECT) 同位素）和治療性核醫學（包括使用 α 和 BETA 發射體的放射性藥物療法，以及用於近距離放射治療的同位素，例如銫-131、碘-125、銥-192 和銫-1923）。這種多層次的分類有助於臨床效用、生產複雜性和監管路徑進行針對性分析。

為了在核子醫學業務擴大策略中做出明智的決策，我們分析了美洲、歐洲、中東和非洲以及亞太市場的區域趨勢和優先促進因素。

核子醫學領域的區域發展趨勢反映了美洲、歐洲、中東和非洲以及亞太地區在投資模式、基礎設施成熟度和法規環境的差異。在美洲，成熟的北美醫療保健系統正在推動先進影像平台和尖端放射性追蹤劑的應用，而拉丁美洲市場則專注於擴展基礎PET和SPECT功能，以滿足日益成長的診斷需求。該地區的相關人員正在努力平衡成本效益高的供應解決方案與對現代治療診斷學方案的需求。

分析推動核子醫學價值鏈創新、卓越營運和競爭優勢的關鍵產業相關人員和策略夥伴關係。

主要企業正積極建立策略聯盟，以加速產品線開發並鞏固市場地位。全球影像設備製造商正與放射性藥物研發公司合作，共同開發端到端解決方案，以最佳化新型示蹤劑的掃描器效能。專業同位素生產商正與合約研發生產機構 (CDMO) 合作，擴大靶向α和BETA發射體的產量；同時，核醫藥局正透過與醫院和診斷中心簽訂許可協議來拓展業務。

為幫助產業領導者最佳化供應鏈、確保合規性以及優先考慮核醫生態系統內的投資提供切實可行的建議。

產業領導者應優先考慮透過投資區域生產能力和建立聯盟式供應協議來實現同位素來源多元化，以此對沖地緣政治風險和貿易中斷。積極參與標準化機構，加強與監管機構的合作，將有助於提高關鍵市場核准流程的一致性，並縮短新化合物進入臨床試驗的時間。此外，將先進的數據分析技術整合到採購和庫存管理中，將提高預測準確性，並最大限度地減少半衰期短的同位素的浪費。

詳細介紹為確保核醫市場情報的數據完整性、全面的市場分析和可靠的檢驗而採用的嚴格調查方法。

本報告的洞見是基於嚴謹的調查方法，結合了第一手和第二手研究、資料三角驗證以及專家檢驗。對同行評審文章、專利申請和監管資料庫的廣泛查閱構成了報告的基礎知識庫。此外，報告還對放射性藥物生產商、影像設備供應商、學術研究中心和監管機構的高管進行了深入訪談，以獲取關於新興趨勢和行業挑戰的第一手觀點。

總結主要研究結果和策略意義，供相關人員參考，以利用新趨勢並塑造核子醫學產業的未來。

先進示蹤劑的研發、數位影像技術的突破以及不斷演進的法規結構的融合，正將核醫學轉變為一個真正以精準為導向的領域。從2025年關稅對供應鏈韌性的影響，到不同產品類型和臨床應用領域細緻細分市場的深入分析，本分析強調了策略適應性和協同創新的重要性。區域趨勢進一步凸顯了採取在地化方法的必要性，這些方法應著眼於本地基礎設施、監管協調和市場成熟度。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 核子醫學市場：依產品類型分類

  • 診斷用放射性藥物
    • 正子斷層掃描（PET）同位素
    • 單光子發射電腦斷層掃描（SPECT）用同位素
  • 治療性核子醫學
    • 用於近距離放射的同位素
      • 銫-131
      • 碘-125
      • 銥-192
      • 鈀-103
    • 放射性藥物療法
      • α粒子發射材料
      • BETA射線放射體

第9章 依給藥方式分類的核醫市場

  • 靜脈注射
  • 口服

第10章 核子醫學市場依應用領域分類

  • 診斷治療
    • PET掃描儀
      • 模擬PET
      • 數字PET
    • SPECT掃描儀
  • 治療

第11章 核子醫學市場：依應用領域分類

  • 循環系統
  • 內分泌學
  • 胃腸病學
  • 神經病學
  • 腫瘤學
  • 整形外科
  • 呼吸內科

第12章 核子醫學市場：依最終用戶分類

  • 學術和研究機構
  • 診斷中心
  • 醫院
    • 公立醫院
    • 私立醫院

第13章 核子醫學市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 核子醫學市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 核子醫學市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國核子醫學市場

第17章：中國核醫市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • 3B Pharmaceuticals GmbH
  • Actinium Pharmaceuticals, Inc.
  • BJ Madan & Co.
  • Bayer AG
  • Bracco SpA
  • BWX Technologies, Inc.
  • Clarity Pharmaceuticals
  • Curium
  • Eli Lilly and Company
  • GE HealthCare
  • IBA
  • Institute of Isotopes Co., Ltd
  • Isotopia Molecular Imaging Ltd.
  • Jubilant Pharma Limited
  • Lantheus Holdings, Inc.
  • Medi-Radiopharma Co., Ltd.
  • Nordion
  • Northstar Medical Technologies LLC
  • Novartis AG
  • Nusano, Inc.
  • PeptiDream Inc.
  • Radiopharm Theranostics Limited
  • SHINE Technologies, LLC
  • Siemens Healthineers AG
  • Sinotau Pharmaceuticals Group
  • South African Nuclear Energy Corporation
  • State Atomic Energy Corporation Rosatom
  • Thor Medical AS by Nordic Nanovector ASA
Product Code: MRR-A339DAEFAF4C

The Nuclear Medicine Market was valued at USD 16.05 billion in 2025 and is projected to grow to USD 17.72 billion in 2026, with a CAGR of 11.25%, reaching USD 33.87 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 16.05 billion
Estimated Year [2026] USD 17.72 billion
Forecast Year [2032] USD 33.87 billion
CAGR (%) 11.25%

Navigating the Evolving Nuclear Medicine Landscape: Foundational Insights Into Modern Diagnostics and Therapeutic Innovations Driving Global Healthcare Progress

Nuclear medicine has emerged as a cornerstone of modern healthcare, harnessing the unique properties of radioisotopes to enable both precise diagnostics and targeted therapies. From early gamma camera imaging to today's sophisticated theranostic approaches, the field has evolved in response to rising demand for personalized care, advances in molecular biology, and relentless innovation in imaging hardware and radiopharmaceutical chemistry. Stakeholders across the value chain-including radiopharmaceutical developers, equipment manufacturers, clinical practitioners, and regulators-are navigating a landscape shaped by shifting clinical guidelines, expanding indications, and heightened scrutiny of safety and supply security.

Against this backdrop, the convergence of digital imaging technologies, novel tracer development, and integrated data analytics is catalyzing a new era of nuclear medicine. Technological strides such as high-resolution detectors, digital positron emission tomography, and hybrid imaging platforms are amplifying diagnostic accuracy, while breakthroughs in targeted alpha and beta emitters are unlocking therapeutic options for oncology, cardiology, and neurology. This introduction lays the foundation for an in-depth exploration of the forces reshaping nuclear medicine, setting the stage for a detailed examination of market drivers, segmentation insights, regional dynamics, and strategic imperatives that will define the industry's trajectory through 2025 and beyond.

Identifying Transformational Shifts Reshaping Nuclear Medicine From Traditional Isotope Protocols to Breakthrough Radiopharmaceutical Developments Across Multiple Modalities

The nuclear medicine landscape is undergoing transformative shifts, originating from breakthroughs in radiopharmaceutical discovery and convergent technological innovations. Recent years have witnessed a surge in novel molecular tracers tailored to specific biomarkers, enabling clinicians to detect pathological processes with unprecedented sensitivity. Concurrently, digital imaging detectors and advanced tomographic reconstruction algorithms have elevated image resolution and quantification capabilities. These dual trends are converging in hybrid platforms that seamlessly integrate positron emission tomography, single photon emission computed tomography, and computed tomography, fostering a more holistic view of disease.

Beyond hardware and tracer advances, the industry is responding to evolving regulatory frameworks that emphasize safety, standardization, and harmonized licensing across jurisdictions. Governments and international bodies are working to streamline radiopharmaceutical approval pathways and improve cross-border supply arrangements, while also enforcing stringent quality controls for isotope production and handling. This regulatory momentum, combined with growing collaboration between academic research institutes and contract manufacturing organizations, is accelerating the translation of preclinical candidates into clinical-grade products. As a result, the sector is poised for a new wave of innovation, where precision diagnostics and targeted therapies coalesce to deliver more effective and efficient patient care.

Assessing the Cumulative Impact of 2025 United States Tariffs on Nuclear Medicine Supply Chains, Research Collaboration Dynamics, and Cross-Border Radiopharmaceutical Trade Flows

The introduction of United States tariffs in 2025 has injected fresh complexity into nuclear medicine supply chains, affecting both isotopic materials and imaging equipment imports. As tariffs on critical raw materials and specialized components took effect, manufacturers faced upward pressure on production costs and logistical constraints. This shift has prompted some producers to reconsider sourcing strategies, invest in domestic isotope generation facilities, and pursue vertical integration to mitigate exposure to import levies.

In tandem, collaborative research networks that once relied on seamless transnational exchange of isotopes and consumables are adjusting to new financial and regulatory burdens. Academic and clinical partners in Europe and Asia are exploring local production partnerships to ensure uninterrupted access to critical radiotracers. Meanwhile, equipment providers have intensified after-sales service and spare-parts stocking in regional hubs to circumvent tariff-driven delays. These adjustments underscore a broader rethinking of the global nuclear medicine ecosystem, where supply resilience and cost containment have become as vital as clinical efficacy for sustaining growth and innovation.

Uncovering Key Market Segmentation Insights Across Product Types, Administration Modes, Usage Categories, Clinical Applications, and End User Profiles for Strategic Clarity

Insights into market segmentation reveal a multifaceted framework that underpins strategic planning and resource allocation. Across product types, the field is delineated into diagnostic radiopharmaceuticals-encompassing positron emission tomography isotopes and single photon emission computed tomography isotopes-and therapeutic nuclear medicine, which includes brachytherapy isotopes such as cesium-131, iodine-125, iridium-192 and palladium-103, alongside radiopharmaceutical therapies employing both alpha emitters and beta emitters. This layered breakdown enables targeted analysis of clinical utility, manufacturing complexity, and regulatory pathways.

The mode of administration distinguishes between intravenous injection and oral ingestion, reflecting divergent pharmacokinetic profiles and patient convenience considerations. Usage patterns are classified into diagnostic procedures and therapeutic procedures, with diagnostic workflows segmented by PET scanner modalities-ranging from analog to digital systems-and SPECT scanners designed for high-resolution imaging. Clinical application categories span cardiology, endocrinology, gastroenterology, neurology, oncology, orthopedics and pulmonology, each driving unique demand trajectories based on disease prevalence and standard-of-care protocols. Finally, end users include academic and research institutes, specialized diagnostic centers, and hospitals-which themselves are segmented into government and private facilities-highlighting the varying operational requirements and procurement processes across the healthcare spectrum.

Analyzing Regional Dynamics and Priority Drivers in the Americas, Europe Middle East Africa, and Asia Pacific Markets for Informed Decisions in Nuclear Medicine Expansion Strategies

Regional dynamics in nuclear medicine reflect divergent investment patterns, infrastructure maturity, and regulatory environments across the Americas, Europe Middle East Africa and Asia Pacific. In the Americas, established healthcare systems in North America drive high adoption of advanced imaging platforms and cutting-edge radiotracers, while Latin American markets focus on expanding basic PET and SPECT capacity to address growing diagnostic needs. Stakeholders in this region are balancing the need for cost-effective supply solutions with demand for the latest theranostic protocols.

Europe Middle East Africa presents a mosaic of adoption rates, with Western Europe leading in standardized regulatory frameworks and collaborative research consortia. Emerging markets in the Middle East and Africa are at earlier stages of establishing isotope generation and distribution networks, often leveraging public-private partnerships to accelerate capability building. Regulatory harmonization efforts are underway to reduce complexity for multinational clinical trials and cross-border collaborations.

Asia Pacific's nuclear medicine sector is characterized by rapid capacity expansion in countries such as China, Japan and India, driven by government initiatives to enhance domestic isotope production and bolster nuclear medicine infrastructure. This region is also a hotbed for technological innovation, with local manufacturers investing heavily in digital imaging detectors and mobile cyclotron installations. As a result, Asia Pacific is emerging as both a consumer and producer of advanced radiopharmaceutical solutions.

Profiling Leading Industry Stakeholders and Strategic Partnerships Fueling Innovation, Operational Excellence, and Competitive Advantage in the Nuclear Medicine Value Chain

Leading companies are forging strategic alliances to accelerate pipeline development and reinforce market presence. Global imaging equipment manufacturers have partnered with radiopharmaceutical developers to co-develop end-to-end solutions that optimize scanner performance for novel tracers. Specialized isotope producers are collaborating with contract development and manufacturing organizations to scale up production of targeted alpha and beta emitters, while nuclear pharmacies are expanding their geographic footprint through licensing agreements with hospitals and diagnostic centers.

In parallel, a new generation of agile start-ups is leveraging proprietary radiochemistry platforms to engineer next-generation theranostic agents, often in joint ventures with academic research institutions. These collaborations are fostering a robust innovation ecosystem, where intellectual property is shared under structured agreements to de-risk development and accelerate regulatory submissions. Equally, established pharmaceutical companies are investing in nuclear medicine capabilities through acquisitions, signaling growing recognition of radiopharmaceuticals as a core component of precision medicine portfolios.

Delivering Actionable Recommendations to Empower Industry Leaders in Optimizing Supply Chains, Regulatory Compliance, and Investment Priorities Within Nuclear Medicine Ecosystems

Industry leaders should prioritize diversification of isotope sourcing by investing in regional production capacity and forming consortium-based supply agreements to hedge against geopolitical and trade disruptions. Strengthening regulatory engagement through active participation in standards-setting bodies will help align approval processes across key markets and reduce time-to-clinic for novel compounds. Moreover, integrating advanced data analytics into procurement and inventory management can enhance forecasting accuracy and minimize waste for short-lived isotopes.

Organizations must also consider forging cross-sector alliances with digital health and artificial intelligence specialists to develop companion diagnostic platforms that personalize treatment pathways. Deploying modular cyclotron technologies in strategic locations will not only improve supply resilience but also drive down logistics costs. Finally, dedicating resources to workforce training and safety protocols will ensure that facilities maintain high compliance standards, safeguard staff and patients, and support sustainable growth in an increasingly complex environment.

Detailing Rigorous Research Methodology Employed to Ensure Data Integrity, Comprehensive Market Analysis, and Robust Validation in Nuclear Medicine Market Intelligence

This report's insights are grounded in a rigorous methodology that combines primary and secondary research, data triangulation and expert validation. An extensive review of peer-reviewed publications, patent filings and regulatory databases provided the foundational knowledge base. Detailed interviews were conducted with senior executives across radiopharmaceutical manufacturers, imaging equipment providers, academic research centers and regulatory authorities to capture firsthand perspectives on emerging trends and industry challenges.

Quantitative data sets covering production volumes, technology adoption rates and demographic trends were analyzed using statistical techniques to identify underlying patterns and correlations. Segmentation analysis was applied across product types, administration modes, clinical applications and end-user categories to ensure that findings are granular and actionable. The resulting conclusions were subjected to multiple rounds of expert review to verify accuracy and relevance, ensuring that the final report delivers robust, evidence-based insights for strategic decision making.

Summarizing Critical Findings and Strategic Implications for Stakeholders to Capitalize on Emerging Trends and Navigate the Future of the Nuclear Medicine Sector

The convergence of advanced tracer development, digital imaging breakthroughs and evolving regulatory frameworks is reshaping nuclear medicine into a truly precision-driven discipline. From the impact of 2025 tariffs on supply chain resilience to the nuanced segmentation insights across product types and clinical applications, this analysis underscores the importance of strategic adaptability and collaborative innovation. Regional dynamics further highlight the need for tailored approaches that address local infrastructure, regulatory alignment and market maturity.

Looking ahead, stakeholders who proactively invest in supply diversification, regulatory harmonization and cross-sector partnerships will be best positioned to capture the next wave of opportunities in theranostics and diagnostic imaging. By leveraging the comprehensive findings outlined in this report, decision-makers can refine their go-to-market strategies, optimize resource allocation and accelerate time-to-clinic for transformative nuclear medicine solutions. This confluence of innovation, regulation and strategic foresight will define the sector's trajectory and its impact on patient care in the coming decade.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Nuclear Medicine Market, by Product Type

  • 8.1. Diagnostic Radiopharmaceuticals
    • 8.1.1. Positron Emission Tomography (PET) Isotopes
    • 8.1.2. Single Photon Emission Computed Tomography (SPECT) Isotopes
  • 8.2. Therapeutic Nuclear Medicine
    • 8.2.1. Brachytherapy Isotopes
      • 8.2.1.1. Cesium-131
      • 8.2.1.2. Iodine-125
      • 8.2.1.3. Iridium-192
      • 8.2.1.4. Palladium-103
    • 8.2.2. Radiopharmaceutical Therapy
      • 8.2.2.1. Alpha Emitters
      • 8.2.2.2. Beta Emitters

9. Nuclear Medicine Market, by Mode Of Administration

  • 9.1. Intravenous Injection
  • 9.2. Oral Ingestion

10. Nuclear Medicine Market, by Usage

  • 10.1. Diagnostic Procedure
    • 10.1.1. PET Scanners
      • 10.1.1.1. Analog PET
      • 10.1.1.2. Digital PET
    • 10.1.2. SPECT Scanners
  • 10.2. Therapeutic Procedure

11. Nuclear Medicine Market, by Application

  • 11.1. Cardiology
  • 11.2. Endocrinology
  • 11.3. Gastroenterology
  • 11.4. Neurology
  • 11.5. Oncology
  • 11.6. Orthopedics
  • 11.7. Pulmonology

12. Nuclear Medicine Market, by End Users

  • 12.1. Academic & Research Institutes
  • 12.2. Diagnostic Centers
  • 12.3. Hospitals
    • 12.3.1. Government Hospitals
    • 12.3.2. Private Hospitals

13. Nuclear Medicine Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Nuclear Medicine Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Nuclear Medicine Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Nuclear Medicine Market

17. China Nuclear Medicine Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. 3B Pharmaceuticals GmbH
  • 18.6. Actinium Pharmaceuticals, Inc.
  • 18.7. B J Madan & Co.
  • 18.8. Bayer AG
  • 18.9. Bracco S.p.A.
  • 18.10. BWX Technologies, Inc.
  • 18.11. Clarity Pharmaceuticals
  • 18.12. Curium
  • 18.13. Eli Lilly and Company
  • 18.14. GE HealthCare
  • 18.15. IBA
  • 18.16. Institute of Isotopes Co., Ltd
  • 18.17. Isotopia Molecular Imaging Ltd.
  • 18.18. Jubilant Pharma Limited
  • 18.19. Lantheus Holdings, Inc.
  • 18.20. Medi-Radiopharma Co., Ltd.
  • 18.21. Nordion
  • 18.22. Northstar Medical Technologies LLC
  • 18.23. Novartis AG
  • 18.24. Nusano, Inc.
  • 18.25. PeptiDream Inc.
  • 18.26. Radiopharm Theranostics Limited
  • 18.27. SHINE Technologies, LLC
  • 18.28. Siemens Healthineers AG
  • 18.29. Sinotau Pharmaceuticals Group
  • 18.30. South African Nuclear Energy Corporation
  • 18.31. State Atomic Energy Corporation Rosatom
  • 18.32. Thor Medical AS by Nordic Nanovector ASA

LIST OF FIGURES

  • FIGURE 1. GLOBAL NUCLEAR MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NUCLEAR MEDICINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NUCLEAR MEDICINE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA NUCLEAR MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NUCLEAR MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET) ISOTOPES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET) ISOTOPES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET) ISOTOPES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) ISOTOPES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) ISOTOPES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) ISOTOPES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY CESIUM-131, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY CESIUM-131, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY CESIUM-131, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY IODINE-125, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY IODINE-125, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY IODINE-125, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY IRIDIUM-192, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY IRIDIUM-192, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY IRIDIUM-192, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PALLADIUM-103, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PALLADIUM-103, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PALLADIUM-103, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ALPHA EMITTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ALPHA EMITTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ALPHA EMITTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY INTRAVENOUS INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY INTRAVENOUS INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ORAL INGESTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ORAL INGESTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ORAL INGESTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ANALOG PET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ANALOG PET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ANALOG PET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIGITAL PET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIGITAL PET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIGITAL PET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY SPECT SCANNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY SPECT SCANNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY SPECT SCANNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PROCEDURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PROCEDURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC PROCEDURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ENDOCRINOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ENDOCRINOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY GASTROENTEROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY GASTROENTEROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ORTHOPEDICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ORTHOPEDICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PULMONOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PULMONOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PULMONOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY GOVERNMENT HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY GOVERNMENT HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY GOVERNMENT HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 229. GCC NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. GCC NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. GCC NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 232. GCC NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 233. GCC NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 234. GCC NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 235. GCC NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 236. GCC NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 237. GCC NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 238. GCC NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 239. GCC NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 240. GCC NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 241. GCC NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 268. G7 NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 269. G7 NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. G7 NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 271. G7 NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 272. G7 NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 273. G7 NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 274. G7 NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 275. G7 NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 276. G7 NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 277. G7 NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 278. G7 NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 279. G7 NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 280. G7 NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 281. NATO NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 282. NATO NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. NATO NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 284. NATO NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 285. NATO NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 286. NATO NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 287. NATO NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 288. NATO NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 289. NATO NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 290. NATO NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 291. NATO NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 292. NATO NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 293. NATO NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 294. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA NUCLEAR MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. CHINA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 311. CHINA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 312. CHINA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 313. CHINA NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 314. CHINA NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 315. CHINA NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 316. CHINA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2018-2032 (USD MILLION)
  • TABLE 317. CHINA NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2018-2032 (USD MILLION)
  • TABLE 318. CHINA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 319. CHINA NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 320. CHINA NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)